Skip to main content

OTC: BWVI

DEVELOPMENT PIPELINE

Explore our Active Programs

BRAIN-DRUG DELIVERY TECHNOLOGIES

Psycheceutical is currently developing products for neuropsychiatric and neurocognitive disorders which are at clinical and pre-clinical stages.

DEVELOPMENT PIPELINE

Our goal is to employ our patented brain-drug delivery strategies to clinically advance FDA-approved psychedelics and Generation 3 therapeutics for neuropsychiatric and neurocognitive disorders in the treatment of mental health and mood disorders.

PSY-007

KETAMINE
INDICATION:

Post Traumatic Stress Disorder (PTSD)

 

STAGE:

Phase I Clinical Trials

 

PSY-007

KETAMINE
INDICATION:

Complex Regional Pain Syndrome (CRPS)

 

STAGE:

CMC

 

PSY-034

UNDISCLOSED
INDICATION:

Addiction

 

STAGE:

CMC

 

PSY-058

UNDISCLOSED
INDICATION:

Parkinson’s Disease

 

STAGE:

Preclinical

 

Our additional IP uniquely focuses on development of brain-drug delivery to combat traumatic brain injuries as we seek to improve functional outcomes for those who suffer from TBI-related conditions.

PSY-311

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

CMC

 

PSY-322

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

PSY-345

UNDISCLOSED
INDICATION:

Traumatic Brain Injury (TBI)

 

STAGE:

Preclinical

 

Discover Our Drug

Delivery Technologies

SUBSCRIBE FOR EMAIL UPDATES:

CLICK HERE

Psycheceutical Bioscience, Inc. (OTC: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines.

© 2023 Psycheceutical, Inc. All Rights Reserved. Website by Domino Brand Consulting.

Legal Disclaimer

Privacy Policy

PSY-007
Post Traumatic Stress Disorder (PTSD)

Market Opportunity:

  • In 2020, about 13 million Americans had PTSD
  • 6 out of every 100 U.S. adults (or 6%) will have PTSD in their lifetime
  • 7 out of every 100 Veterans (or 7%) will have PTSD in their lifetime
  • VA research estimates the annual economic burden of PTSD at $232 billion (2018)
  • The global market for PTSD drugs is expected to reach $26.1 billion by 2031

Technology:

  • Patented NeuroDirect™ technology
  • Provisional Patent of PSY-007 filed for PTSD
  • Novel delivery strategy of FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • Safe and accessible treatment option for PTSD
Explore The NeuroDirect™ Technology
PSY-007
Complex Regional Pain Syndrome (CRPS)

Market Opportunity:

  • CRPS affects nearly 200,000 U.S. patients annually
  • Impairs function, sleep, and activities of daily living
  • Associated with worsening depression, anxiety, and diminished quality of life
  • Current medications for CRPS have adverse side effects

Technology:

  • Patented NeuroDirect™ technology
  • Novel delivery strategy of FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • 7-year exclusivity
Explore The NeuroDirect™ Technology
PSY-034
Addiction

Market Opportunity:

  • 20.4 million Americans suffered from a substance use disorder (SUD) in 2019
    • 14.5 million people suffered from an alcohol use disorder
    • 8.3 million people suffered from an illicit drug use disorder 
    • 2.4 million people suffered from both
  • Research estimates the annual economic cost of SUD in the U.S. is approximately $3.73 Trillion
  • Global market for SUD treatment expected to reach $23.1 billion by 2031 

Technology:

  • Patented NeuroDirect™ technology
  • Novel delivery strategy to avoid side effects
  • Use for investigation and treatment of addiction
Explore The NeuroDirect™ Technology
PSY-058
Parkinson’s Disease

Market Opportunity:

  • Nearly one million people in the U.S. are living with Parkinson’s Disease (PD)
  • Nearly 90,000 people in the U.S. are diagnosed with PD each year
  • PD is the second-most common neurodegenerative disorder in the U.S.
  • Has no cure, only symptom relief with added side-effects
  • Global market for PD drugs expected to reach $10.4 billion by 2031

Technology:

  • Patented NeuroDirect™ technology
  • Patented PSY-058 for PD
  • Novel delivery strategy of FDA-approved compound to avoid side effects
  • 505(b)(2) IND-filing to expedite market access
Explore The NeuroDirect™ Technology
PSY-311
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • New chemical entity
  • Licensing agreements under negotiations
  • Use for investigation and treatment of TBI and the causes of neuroinflammatory pathology
PSY-322
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • New chemical entity
  • Licensing agreements under negotiations
  • Use for investigation and treatment of TBI and the causes of neuroinflammatory pathology
PSY-345
Traumatic Brain Injury (TBI)

Market Opportunity:

  • Over 5 million Americans suffer from a disability related to TBI
  • There were over 69,000 TBI-related deaths in the U.S. in 2021
  • 80% of TBI are mild and are often undiagnosed
  • No FDA-approved drugs for treating symptoms of mild TBI
  • Global market for TBI treatments is expected to reach USD 201.1 billion by 2029

Technology:

  • Novel indication of an FDA-approved compound
  • 505(b)(2) IND-filing to expedite market access
  • Use for Investigation and treatment of TBI and the causes of neuroinflammatory pathology

GET EMAIL UPDATES FROM PSYCHECEUTICAL, INC.

Fill out the form below to get updates delivered directly to your inbox.